logo
  

H.B. Fuller Q3 Profit Down

H.B. Fuller Company (FUL) Wednesday reported third-quarter net income of $31.6 million or $0.58 per share, down from $41.6 million or $0.79 per share last year.

Adjusted earnings for the quarter rose to $0.79 per share from $0.76 per share last year.

Revenues for the quarter rose 20% to $826.8 million from $691.5 million last year. Organic revenue increased 16%, with 10% from volume growth and 6% from pricing.

Analysts polled by Thomson Reuters expected earnings of $0.79 per share on revenues of $797.48 million for the quarter.

Moving ahead, the company said that strategic supply chain management enabled it to secure raw materials to meet increasing demand, and pricing actions have been implemented that are expected to restore margins in the fourth quarter and into 2022.

The company expects full-year revenue growth to be 17% to 18% and fourth quarter revenue growth of 15% to 17%. Analysts currently estimate revenue growth of 14.40% and 8.10%, respectively.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated.. Covid vaccine maker Moderna Inc.'s Chief Executive Stéphane Bancel has predicted that existing COVID-19 vaccines will be much less effective against Omicron than earlier strains, according to the Financial Times.
RELATED NEWS
Follow RTT